CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $7.5M, lower than 95% of all stocks globally
- PositionOperating margin is -4974.3%, lower than 95% of its Biotechnology peers (median -23.4%)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.52BUSDvs all stocks (USD)
Revenue (TTM)
7.50MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.6040xvs all stocks
52-Week Change
-14.09%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
3.52BUSDvs all stocks (USD)
Enterprise Value
2.56BUSDvs all stocks (USD)
Forward P/E
-7.62xvs Biotechnology peers
Price to Book (MRQ)
2.80xvs Biotechnology peers
Enterprise to Revenue
341.73xvs Biotechnology peers
Enterprise to EBITDA
-5.84xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-4974.27%vs Biotechnology peers
Return on Assets (TTM)
-28.02%vs Biotechnology peers
Return on Equity (TTM)
-43.62%vs Biotechnology peers
Revenue (TTM)
7.50MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0946USDUpdated Oct 28, 2026Gross Profit (TTM)
-352.48MUSDvs all stocks (USD)
EBITDA (TTM)
-439.19MUSDvs all stocks (USD)
Net Income (TTM)
-409.20MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-337.52MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-203.55MUSDvs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00USDUpdated Oct 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
7.50MUSDFY2025 · Dec 31, 2025Operating Income
-373.07MUSDvs all stocks (USD)
Pre-tax Income
-344.89MUSDFY2025 · Dec 31, 2025Income Tax Expense
1.02MUSDFY2025 · Dec 31, 2025Net Income
-345.91MUSDFY2025 · Dec 31, 2025EBIT
-373.07MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-371.88MUSDFY2025 · Dec 31, 2025Research & Development
300.94MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
79.63MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
26.83MUSDFY2025 · Dec 31, 2025EPS (Basic)
-4.36USDFY2025 · Dec 31, 2025EPS (Diluted)
-4.36USDFY2025 · Dec 31, 2025Basic Shares Outstanding
79.25MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
79.25MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-345.91MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-289.54MUSDFY2025 · Dec 31, 2025Free Cash Flow
-290.34MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
199.16MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-345.91MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.54MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-3.20MUSDFY2025 · Dec 31, 2025Stock-based Compensation
53.71MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.31MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
104.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
1.90MUSDFY2025 · Dec 31, 2025Capital Expenditures
-799.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-355.66MUSDFY2025 · Dec 31, 2025Sale of Investments
574.45MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
218.00MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
112.15MUSDFY2025 · Dec 31, 2025Shares Outstanding
96.75MSharesUpdated Oct 28, 2026Float Shares
90.90MSharesUpdated Oct 28, 2026Shares Short
7.35MSharesUpdated Oct 28, 2026Short Ratio
2.61daysvs all stocks
Short % of Shares Outstanding
7.60%vs all stocks
% Held by Insiders
0.17%vs all stocks
% Held by Institutions
107.39%vs all stocks
Total Cash (MRQ)
930.69MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
9.61USDUpdated Oct 28, 2026Total Debt (MRQ)
6.42MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0052xvs Biotechnology peers
Current Ratio (MRQ)
21.02xvs Biotechnology peers
Book Value per Share (MRQ)
12.84USDUpdated Oct 28, 2026Total Assets
633.16MUSDvs all stocks (USD)
Total Current Assets
560.65MUSDFY2025 · Dec 31, 2025Total Liabilities
51.40MUSDFY2025 · Dec 31, 2025Total Non-current Assets
72.51MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
9.61MUSDFY2025 · Dec 31, 2025Total Current Liabilities
41.79MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
199.16MUSDFY2025 · Dec 31, 2025Other Short-term Investments
349.72MUSDFY2025 · Dec 31, 2025Accounts Receivable
1.37MUSDFY2025 · Dec 31, 2025Accounts Payable
3.88MUSDFY2025 · Dec 31, 2025Short-term Debt
1.53MUSDFY2025 · Dec 31, 2025Long-term Debt
6.41MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
3.20MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.60BUSDFY2025 · Dec 31, 2025Retained Earnings
-1.25BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
581.76MUSDvs all stocks (USD)
52-Week Low
33.38USDUpdated Oct 28, 202652-Week High
72.66USDUpdated Oct 28, 202652-Week Change
-14.09%vs all stocks
Beta
0.6040xvs all stocks
50-Day MA
46.83USDUpdated Oct 28, 2026200-Day MA
52.43USDUpdated Oct 28, 2026Avg 10-Day Volume
1.16MSharesUpdated Oct 28, 2026Avg 30-Day Volume
2.41MSharesUpdated Oct 28, 2026Diluted EPS (TTM)
-4.74USDUpdated Oct 28, 2026Other Income / Expense
1.35MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -4974.3%, lower than 95% of its Biotechnology peers (median -23.4%)Significant
Operating margin: -49.74Industry median: -0.23Industry P5: -23.37Peers compared: 184
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.72
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $7.5M, lower than 95% of all stocks globallySignificant
Revenue (USD): 7,500,000Global P5: 36,021,613.518
Market cap is $3.52B, above the global median of $1.14BNotable
Market cap (USD): 3,519,181,298Global Median: 1,138,591,906.897
Companies that share the same coordination system — how they create, deliver, or capture value.
Hypera S.A.
Tier 1ProductionApproval-Gated PipelineRule
Pegbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ambu A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hybio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hualan Biological Engineering Inc.
Tier 1ProductionApproval-Gated PipelineRule
Disc Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Jumpcan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Tiantan Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Laboratorios Farmacéuticos Rovi SA
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Hyliion Holdings Corp.
3 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity
IonQ, Inc.
2 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Opus Genetics Inc.
2 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated